Related guidance

NICE Clinical Guideline CG127 (2011): Hypertension: Clinical management of primary hypertension in adults
NICE Clinical Guideline CG180 (2014): Atrial fibrillation
NICE Clinical Guideline CG172 (2013): MI: secondary prevention
NICE Clinical Guideline CG107 (2010): Hypertension in pregnancy
NICE Clinical Guideline CG108 (2010): Chronic heart failure
NICE Clinical Guideline CG126 (2012): Stable angina: Management
NICE Technology Appraisal TA210 (2010): Clopidogrel and modified-release dipyridamole


2.1 Positive inotropic drugs
2.2 Diuretics
2.3 Anti-arrhythmic drugs
2.4 Beta-adrenoreceptor blocking drugs
2.5a Care Pathway for Hypertension
2.5b Summary Drug Treatment for Hypertension
2.5c Prescribing Guidelines Heart Failure
2.5.5 Drugs affecting the renin-angiotensin system
2.6 Nitrates, CCBs and potassium channel activators
2.6 Primary Care Guidelines for drug treatment of Chronic Stable Angina Pectoris
2.6.3 Other antianginal drugs
2.6.4 Peripheral vasodilators
2.8 Anticoagulant drugs
2.8.2 Oral anticoagulants
2.8.2 Drug Interactions for Apixaban, Dabigatran, Edoxaban and Rivaroxaban
2.8.2 Decision aid for patients requiring stroke prevention in AF
2.8.2 Reducing the risk of stroke in Atrial Fibrillation - NICE CG180 (including decision aid)
2.8.2 NOAC implementation priorities
2.9 Antiplatelet drugs
2.12 Lipid regulating drugs

Given the wide overlap between many drug groups and clinical indications , the indications for which each drug is included in the formulary are clearly stated in the comments section. Recommendations and local guidelines for the management of specific cardiovascular conditions as provided in inserts.
– Hypertension
– Heart Failure
– Primary Care Guidelines for the Treatment of Chronic Stable Angina Pectoris
-Management of anticoagulant-induced haemorrhage
-Primary Prevention of CVD
-Secondary Prevention of CVD
-Drug – statin interactions table